Positive results announced for metastatic tumour treatment
A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial.
DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours.
According to Kainova, the study conducted France and Belgium met all primary objectives. Results demonstrated a favourable safety profile, robust pharmacokinetic (PK) and pharmacodynamic (PD) characteristics with dose-proportional exposure, and sustained EP4 receptor engagement across all tested doses, with early signs of anti-tumour activity. No dose-limiting toxicities were reported at any dose level.
“The Phase I EPRAD study generated a clear and coherent dataset that precisely characterises DT-9081’s clinical profile,” said Dr Jean-Marie Cuillerot, Chief Medical Officer of Kainova Therapeutics.
“Across all dose levels, we observed consistent safety findings together with robust PK/PD readouts. The high-quality clinical and translational data obtained in this study are essential for understanding how EP4 antagonism behaves in patients with advanced solid tumours in a clinical setting.”
“The successful completion of this Phase I study represents an important step for Kainova Therapeutics, highlighting the strength of our innovative approach to targeting the EP4 receptor to overcome tumour-induced immunosuppression,” added Sean MacDonald, Chief Executive Officer of Kainova Therapeutics.
“The favourable safety and early efficacy signals observed with DT-9081 provide meaningful insight into EP4 biology and its role in immuno-oncology. These findings reflect the depth of expertise within our team and reinforce the relevance of GPCR-modulating strategies in addressing complex immune pathways.”
